{"id":"NCT03861559","sponsor":"Organon and Co","briefTitle":"Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)","officialTitle":"Onset of Action of Mometasone Furoate (SCH 32088) Nasal Spray 50 mcg/Spray vs Placebo in Seasonal Allergic Rhinitis (Study No. C93-184).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1994-03-30","primaryCompletion":"1994-06-27","completion":"1994-07-07","firstPosted":"2019-03-04","resultsPosted":"2019-09-20","lastUpdate":"2022-02-09"},"enrollment":201,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rhinitis, Allergic, Seasonal"],"interventions":[{"type":"DRUG","name":"mometasone furoate nasal spray","otherNames":["NASONEXÂ®","MK-0887","SCH 032088"]},{"type":"DRUG","name":"placebo nasal spray","otherNames":[]}],"arms":[{"label":"mometasone furoate nasal spray","type":"EXPERIMENTAL"},{"label":"placebo nasal spray","type":"PLACEBO_COMPARATOR"}],"summary":"This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.","primaryOutcome":{"measure":"Median Time to Onset of Nasal Symptom Relief as Assessed by Participant Diary Responses","timeFrame":"From the start of treatment until onset of symptom relief (up to Day 4)","effectByArm":[{"arm":"Mometasone Furoate Nasal Spray","deltaMin":35.9,"sd":null},{"arm":"Placebo Nasal Spray","deltaMin":72,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.01"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":101},"commonTop":["Headache"]}}